Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
HCRN GU22-598
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
- NCT06809140 ↗
- Recruiting
- Matthew Galsky
- Focused
We haven't built an HCP commentary report on HCRN GU22-598 (enfortumab vedotin and pembrolizumab in Muscle Invasive Bladder Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HCRN GU22-598 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 2 Trial of Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Urothelial Cancer of the Bladder
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma
- Interventions
- Enfortumab vedotin; Pembrolizumab
- Arms
- Enfortumab vedotin plus pembrolizumab · Experimental
- Enrollment
- 75 (estimated)
- Primary outcomes
- Complete response rate with enfortumab vedotin plus pembrolizumab for MIBC
- Bladder-intact event-free survival (BIEFS) in patients achieving a clinical complete response
- Sponsor
- Matthew Galsky with Seagen Inc., Astellas Pharma Inc, Merck Sharp & Dohme LLC, Icahn School of Medicine at Mount Sinai
- Start
- Apr 7, 2025
- Primary completion
- Nov 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06809140 · updated Aug 5, 2026